- Home
- GNW vs MRUS Comparison
GNW vs MRUS Comparison
Compare GNW & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNW | MRUS |
|---|---|---|
| Founded | 1871 | 2003 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 5.1B |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GNW | MRUS |
|---|---|---|
| Price | $8.82 | $96.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 17 |
| Target Price | $10.00 | ★ $94.94 |
| AVG Volume (30 Days) | ★ 4.0M | 1.4M |
| Earning Date | 11-05-2025 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.86 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $7,299,000,000.00 | $56,606,000.00 |
| Revenue This Year | N/A | $56.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.40 | ★ N/A |
| Revenue Growth | N/A | ★ 57.54 |
| 52 Week Low | $5.99 | $33.19 |
| 52 Week High | $9.15 | $96.94 |
Technical Indicators
Market Signals| Indicator | GNW | MRUS |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 74.48 |
| Support Level | $8.58 | $96.60 |
| Resistance Level | $9.06 | $96.83 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 61.40 | 97.92 |
Price Performance
Historical ComparisonAbout GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.